Curated News
By: NewsRamp Editorial Staff
July 15, 2026

Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Quantum BioPharma's LUCID-MS, targeting myelin repair, offers a first-in-class advantage over immune-modulating MS therapies.
  • LUCID-MS passed Phase 1 safety trials; Quantum BioPharma filed an IND for Phase 2 studies in MS patients.
  • LUCID-MS aims to restore myelin and slow neurodegeneration, potentially improving quality of life for people with multiple sclerosis.
  • Quantum BioPharma's LUCID-MS reverses myelin degradation in preclinical models, a novel approach to treating multiple sclerosis.

Impact - Why it Matters

This news matters because it highlights a potential breakthrough in multiple sclerosis treatment. Unlike current therapies that focus on immune modulation, LUCID-MS directly targets myelin repair and neuroprotection. For the millions living with MS, this could mean a treatment that addresses the root cause of disability—demyelination—rather than just managing symptoms. If successful in Phase 2 trials, LUCID-MS may offer a first-in-class option that could slow or reverse disease progression, significantly improving quality of life. Investors and patients alike should watch this development closely.

Summary

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS. The company reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile and that the therapy was generally well tolerated, supporting advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. The therapy aims to target demyelination and protect or restore myelin integrity, offering a potentially first-in-class approach that directly addresses myelin loss and neurodegeneration rather than relying solely on immune modulation. The company is strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists.

Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Additionally, Quantum BioPharma invented unbuzzd and spun out its OTC version to Unbuzzd Wellness Inc., retaining 19.84% ownership and a royalty agreement. The company retains 100% rights to develop similar products for pharmaceutical and medical uses. More information is available at www.unbuzzd.com.

For full details, including forward-looking statements, terms of use, and disclaimers, visit the InvestorBrandNetwork website and the company’s newsroom at https://ibn.fm/QNTM. The original release can be viewed at www.newmediawire.com.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis

blockchain registration record for this content.